Trichostatin A (TSA)

Catalog No.S1045

Trichostatin A (TSA) Chemical Structure

Molecular Weight(MW): 302.4

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

Size Price Stock Quantity  
USD 247 In stock
USD 447 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 113 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Targets
HDAC [1]
(Cell-free assay)
~1.8 nM
In vitro

Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. [1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. [2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 NFrPTZRHfW6ldHnvckBCe3OjeR?= MonPNE44|ryP MWiyOIg> M3nkU4V1cGGwb3y= MkW0[Y5p[W6lZYOgSW5iSyCjY3X0fYxifGmxbjDhcoQhcW6lcnXhd4V{KEWQYVOgZYJ2dmSjbnPlJIlvKHSqZTD0c5RidCClZXzsJIx6e2G2ZTDhcoQh[XRidHjlJINmdGxic4Xy[oFk\Q>? M1qwcFI2Pzh5MEe5
TE13 NGXwTmZHfW6ldHnvckBCe3OjeR?= MmjNNE4{|ryP NH;MTHczPGh? MUD1dE1z\We3bHH0[ZMhWkGVU1[1RUBt\X[nbB?= NHrMWoIzPTV5OU[2OS=>
TE13 M136ZmFxd3C2b4Ppd{BCe3OjeR?= M1fDTFAvO87:TR?= MV2yOIg> NX7hempEcW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbh?= NWrzeVF{OjV3N{m2OlU>
MEFs NGnoN2FHfW6ldHnvckBCe3OjeR?= Mn;wOe69VQ>? NFnVWosyPmh? MnTzbY5kemWjc3XzJJRp\SCHUFXDJIF1fGGlaH3lcpQtKFSrcjDk[YxqfmW{eTDhcoQhfGinIHXm[olkcWWwY4mgc4YheGWmZYP0ZYwh\m:{bXH0bY9v NF3IUJQzPTR6Mk[zOC=>
SW480  Mn3XSpVv[3Srb36gRZN{[Xl? MYGwMlHPxE1? NFTGRWg1QGh? M4HWO2ROW09? NW[wdo15emW4ZYLz[ZMhTU2W MVOyOVQ{PDl7Nx?=
PC3  NH7TV41HfW6ldHnvckBCe3OjeR?= MVqwMlHPxE1? M36wPVQ5cA>? M3\GeGROW09? NGn5W2hz\X[ncoPld{BGVVR? M2jodlI2PDN2OUm3
SW480  MUfGeY5kfGmxbjDBd5NigQ>? M{Gxb|AvOc7:TR?= M3jDPFQ5cA>? MULEUXNQ NX\CdY1t[XS2ZX71ZZRmeyCrbo\hd4lwdiCjbnSgcYloemG2aX;u MnjZNlU1OzR7OUe=
PC3  NYDtR|RtTnWwY4Tpc44hSXO|YYm= Ml7qNE4y|ryP M4XPcFQ5cA>? MmHMSG1UVw>? MWHheJRmdnWjdHXzJIlvfmG|aX;uJIFv\CCvaXfyZZRqd25? MlP6NlU1OzR7OUe=
SW480  MXLGeY5kfGmxbjDBd5NigQ>? NGXLOFYxNjIQvF2= MXu0PIg> MmOzSG1UVw>? MlXabY5lfWOnczDpcoNz\WG|ZTDv[kBJTEGFMTDhcoQhUESDQ{Kgc44hW2y3ZzDn[Y5meyCycn;tc5Rmeg>? NGnMWG0zPTR|NEm5Oy=>
PC3  MnKySpVv[3Srb36gRZN{[Xl? MYmwMlHPxE1? MXe0PIg> M1vUbmROW09? MVPpcoR2[2W|IHnuZ5Jm[XOnIH;mJGhFSUNzIHHu[EBJTEGFMjDvckBUdHWpIHflcoV{KHC{b33veIVz M{\LUVI2PDN2OUm3
A431 MVPBdI9xfG:|aYOgRZN{[Xl? MYKyM|ExNzVyL{GwNI5O NXnEVINsPDiq M1[ydGROW09? NU\MZnJjcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4To MUSyOVM4OTB4OR?=
A431 MV7GeY5kfGmxbjDBd5NigQ>? NWnBWYZzPTCwTR?= NF7kVY0zNzZxMUKvNlRp MojUSG1UVw>? NWHvZpFi[WO2aY\heIV{KHB{MTDhcoQhcW6qaXLpeJMhSVSIMzDlfJBz\XO|aX;u NHzVOGwzPTN5MUC2PS=>
MDA-MB-231 MkD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4THSlAuPjBybl2= MW[yOIg> NFfWO2dFVVOR M2PTN2lEPTBib3[gNVAxdk1? NVGzfG5{OjVzOUK3NlE>
MCF7 M2Dvbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTMbYxbOC14MEDuUS=> MlHONlRp NWrkcVBHTE2VTx?= NFjMZVFKSzVyIH;mJFc2dk1? NI\tfnczPTF7MkeyNS=>
SKOV-3 NH\WZXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LvTVEuOTEQvF2= NVvGTIczOjSq MUXEUXNQ MUHJR|UxKG:oIEWuOu69VQ>? MnnzNlUyPjl2OUG=
A549 MlrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3T2OlEuOTEQvF2= MXWyOIg> Mke2SG1UVw>? MoTDTWM2OCCxZjCzMlLPxE1? NVvGfIJvOjVzNkm0PVE>
SKOV-3 NIjU[WNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\BOJBoOC5zLUJOwG0> M1fo[lQ5cA>? MX7EUXNQ M1PaOWlEPTBib3[gNE44|ryP NIrle5kzPTF4OUS5NS=>
A549 NHrQTI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEL3RY0xNjFvMd88US=> NYTZWmNOPDiq MkPUSG1UVw>? NVfCfHpZUUN3MDDv[kAxNjJ6zszN NG\peGkzPTF4OUS5NS=>
SKOV-3 NVHwcItGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfaTYMxNjBzLUCuPe69VQ>? NGm1NFg4Omh? NXvwdHpiTE2VTx?= M3qzOGlEPTBib3[gNE4{Os7:TR?= Mn7hNlUyPjl2OUG=
A549 Ml63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVmwMlAyNTBwOd88US=> NFjTNGM4Omh? MnXwSG1UVw>? M1mwfmlEPTBib3[gNE4xPs7:TR?= Ml3aNlUyPjl2OUG=
HeLa NFnuTmNHfW6ldHnvckBCe3OjeR?= MYCyOVBvVQ>? NIHNO5MyPmh? NEi2cmNFVVOR MlLXbY5kemWjc3XzJGN[WDGDMTDtVm5CKGW6cILld5Nqd28EoB?= NUm4cYYzOjVzMU[2PFg>
CNE2 NGXrT3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2W2RlExOC14MEDuUS=> NITNN4gzPC92OD:3Nog> M1;MfYlvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MkLWNlQ6Pjl7MEG=
PC3 M4PIVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPINVAxNTFyMEDuUS=> MXOyOIg> Mnr0TWM2OCCxZjCzNFBvVQ>? M{Dj[FI1QDV2NkW4
LNCaP MlfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4roTVExOC1zMECwcm0> MUmyOIg> NWXoWXd6UUN3MDDv[kA{ODCwTR?= M2jGZlI1QDV2NkW4
HeLa  MnizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3q0ZVLPxE1? M2mxblQ5cA>? NWXLd2tj\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIFjd3W2IEK1KS=> Ml:zNlQ5PDZzM{W=
HMEC-1  NXGyZnZWTnWwY4Tpc44hSXO|YYm= NIrYfWM{ODCwTR?= M3zvcFI1cA>? NFy4e2tqdmO{ZXHz[ZMh\XiycnXzd4lwdiCxZtMgWmVITlJ|wrDtVm5C NH;hTWUzPDdzME[zNS=>
HeLa M{HQUGZ2dmO2aX;uJGF{e2G7 MlmwNY1O MnLJNE42cA>? NXTGU4Jv[WKxbHnzbIV{KHSqZTD0c5RidCCKRFHDJIFkfGm4aYT5 MoPqNlQ4ODd2N{S=
ACP02 NHPCd21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M36zelI2OC9|NUCvOVAxdk1? NWPH[W1OOjSq NHXSSpFl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgc4Yh[XCycn;4bY1ifGWueTC3NOKhLSCjdDCyOVDDqG6P NH\Jb40zPDZ4OEW0Oy=>
ACP03 NWrkU3ZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;ESndYOjVyL{O1NE82ODCwTR?= NUfuW2ZpOjSq NX3VdYJC\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JI9nKGGycILvfIlu[XSnbImgO|DDqCViYYSgNlUxyqCwTR?= MoHtNlQ3Pjh3NEe=
U87 GBM NFHzUIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vRSlExOC9|MECvOVAxKG6P NInlUlc4OiCq NUTpO45MOTByJTDleIhidm:u MnLXdoVlfWOnczDt[YFvKGOnbHygcpVu[mW{IHL5JFMyNCB3NDygZY5lKDV6wrCl MV2yOFQ3PDh2MR?=
U87 GBM MYXGeY5kfGmxbjDBd5NigQ>? MnvjNVAxNzVyMDDOcS=> NIC4flc1QCCq NV\2RYM1OTByJTDleIhidm:u NH73U45KdmS3Y3XzJHNmdmW|Y3XuZ4UuVGmtZTDBcJRmemG2aX;ud{BqdiCQdXPs[YFzKE2xcoDoc4xw\3l? MV:yOFQ3PDh2MR?=
RPE MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\UNE4zNzBwND:wMlgwOSEQvF2= Mlj0NlQwPDhxN{KgbC=> M2PQOGROW09? MYXpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDifUBk\WyuIHP5Z4xmKGG{cnXzeC=> M2W0[FI1PDV4NkCy
HT29  NVfzdJBHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jENFE5OCCwTR?= MUm3NkBp M4L6WmlEPTBib3[gNVgxKG6P NFHxcJEzPDN4OEK2OS=>
hMSCs M{D2XmZ2dmO2aX;uJGF{e2G7 MYO2MlI2KG6P M1G3W|I1KGh? NX\1NZp[TE2VTx?= M4P0dJN1[WKrbHn6[ZMhUGm|dH;u[UBC[2W2eXzheIlwdiCjbnSgeIhmKEW6cILld5Nqd25ib3[gVIx2emmyb4TlcpQhT2WwZYO= NI\3fXAzPDNzMkO1Oi=>
Huh7  NWi3OpI6TnWwY4Tpc44hSXO|YYm= NFjUb3oxNjFxMD61M|EvOCEQvF2= NHG1WI8zPGh? M{nhXZN2eHC{ZYPz[ZMhYVSKRFOyJIdmdmViZYjwdoV{e2mxbh?= NIDGN4wzPDJ4OU[3Ni=>
SKOV3 MnO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrDNWdsOC5yNT2yJO69VQ>? MoW1NVAwOjRxNEigbC=> NYLkOZN1TE2VTx?= NHP4WoZu\WSrYYTld{Boem:5dHigZZJz\XO2IHnuJIEh[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= MUOyOFIzOzhyMR?=
A2780 M3\kdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXtOVJ[OC5yNT2yJO69VQ>? NVrkTZJPOTBxMkSvOFghcA>? M2XEWGROW09? NGDIeIdu\WSrYYTld{Boem:5dHigZZJz\XO2IHnuJIEh[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NGLuSWgzPDJ{M{iwNS=>
SRA01/04  NXS1O2pvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLl[3h3OC5{IN88US=> Mnr2OFghcA>? M4LkUmROW09? MVnzeZBxemW|c3XzJINmdGxicILvcIln\XKjdHnvckB1cHKxdXfoJJN2eHC{ZYPzbY5oKHSqZTDQTVNMN0GtdDygdFM5VUGSSzDhcoQhTVKNMT:yJJNq\26jbHnu[{Bx[XSqd3H5dy=> M2TodlI1OTV5OEe4
HLEB3 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTtSVhNOC5{IN88US=> M3nLe|Q5KGh? MVzEUXNQ MYLzeZBxemW|c3XzJINmdGxicILvcIln\XKjdHnvckB1cHKxdXfoJJN2eHC{ZYPzbY5oKHSqZTDQTVNMN0GtdDygdFM5VUGSSzDhcoQhTVKNMT:yJJNq\26jbHnu[{Bx[XSqd3H5dy=> M2fCPVI1OTV5OEe4
SRA01/04  NXW0ZYVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYiwMlQwOC56IN88US=> Mlq4OFghcA>? M4LjZmROW09? MXnpcoR2[2W|IHPlcIwh[XCxcITvd4l{ M2LXblI1OTV5OEe4
HLEB3 NFSxbotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjabJYxNjRxMD64JO69VQ>? MlX1OFghcA>? MX\EUXNQ MkjjbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MYmyOFE2Pzh5OB?=
HCT116 M4L0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzxXml3OC5{IN88US=> M13mT|EzKGh? NGPaUm5mdmijbnPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JJJi\GmjdHnvci=> MXyyOFEzOjJ|MR?=
CA46 NUG3W2dnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jPcFMwPi9zMj:yOE81QCCwTR?= NGDh[FU1QCCq M3zXfYlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iYYSgNlQh[W6mIES4JI5OyqB? MYqyOFA3PDl3MR?=
PMNs M3zpPGZ2dmO2aX;uJGF{e2G7 NEDwRoY{OCCwTR?= NG\5co01QCCq NXj2NndFcW6qaXLpeJMh\W[oZYLvZ5l1d3OrczygTGRCSyCjY4Tpeol1gSCjbnSgVoFkKGGldHn2bZR6 NF3tdo4zOzl6OE[xOy=>
H1299 NXfNWZB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\FcGEyyqEQvF5CpC=> M{[yTlI1NzR6L{eyJIg> NEDidpZmfGijbn;s MV\pcoNz\WG|ZYOgZ4VtdCCmZXH0bEBi\nSncjCyOIg> NVztZY94OjN7MU[2NFk>
A549 Mn;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFq1TG0xNjJ3L{CuOU8yKM7:TR?= M32wTFI1NzR6L{eyJIg> M13tNIV1cGGwb3y= MnjwbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHnuJINwdmOnboTyZZRqd25iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? M1jHTFI{QDZ5OUmx
H1299 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TEbVAvOjVxMD61M|Eh|ryP MlLGNlQwPDhxN{KgbC=> Mof3[ZRp[W6xbB?= MkLsbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHnuJINwdmOnboTyZZRqd25iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? MUGyN|g3Pzl7MR?=
A549 NGfyW4JCeG:ydH;zbZMhSXO|YYm= MV:wMlUwOSEQvF2= M{fpRlQ5KGh? Ml;y[ZRp[W6xbB?= Mn;pbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MUmyN|g3Pzl7MR?=
H1299 MnrtRZBweHSxc3nzJGF{e2G7 M4PKOlAvPS9zIN88US=> M4TTT|Q5KGh? NILmTYZmfGijbn;s MUPpcoR2[2W|IHPlcIwh[XCxcITvd4l{ Ml;DNlM5Pjd7OUG=
SUM149PT MmiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWThcnp2Oi95LkWvNVAh|ryP M1G4SFQ5KGh? MUTEUXNQ MX3pcoR2[2W|IHPlcIwh\GWjdHigZZQhOiEQvF2gbY5{\W6|aYTpeoVtgQ>? M3vXNFI{Pzl{NkO4
SUM190PT NIe5OoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;KOVAwOTByL{K1NEBvVQ>? MVq0PEBp M2C3[mROW09? MXvpcoR2[2W|IHPlcIwh\GWjdHigZZQhPTBibl2gd4Vve2m2aY\lcJk> M2XTbVI{Pzl{NkO4
HCT1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVywMlIwOS5yL{WuNEDPxE1? NVLMbHQ3OTJxMkSvN|YwPDhiaB?= M{PKcIlv\HWlZYOgZ4VtdCCmZXH0bEBqdiClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy M3TlO|I{PzdyMECw
Lovo MmrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWGwMlIwOS5yL{WuNEDPxE1? MUCxNk8zPC9|Nj:0PEBp NED5OWdqdmS3Y3XzJINmdGxiZHXheIghcW5iY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> NHnF[JUzOzd5MECwNC=>
AGS NWi4OGp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrXUWtSOC5yMUWtNUDPxE1? NYf0XZgyPzJiaB?= NW\nflRLcW6mdXPld{Bk\WyuIHTlZZRpKGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk> Mm\oNlM4PDVyMkS=
Huh7 NYXTNoprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7aTFNiOSEQvF2= NHfKO|czPCCq NH7RXWtFVVOR NVjxWm4{emWmdXPld{Bi[m:3dDCyNEUhfmmjYnnsbZR6yqB? NWrzfWoyOjN4NEO5N|M>
ECC1 M3rmU2Z2dmO2aX;uJGF{e2G7 MU[1NFAhdk1? MXO1JIQ> MWXEUXNQ NHPTVpZqdmS3Y3XzJGwyS0GPwrDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?= M{LpOVI{PTNyN{[5
HEC1A NIjPNm5HfW6ldHnvckBCe3OjeR?= NInjbHo2ODBibl2= NUe3XmZDPSCm NFXDUlVFVVOR M4ToW4lv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF NHXS[lgzOzV|MEe2PS=>
EN1 NYe4NVUxTnWwY4Tpc44hSXO|YYm= NIm3VoY2ODBibl2= MlixOUBl M2rTbmROW09? NHvPeHBqdmS3Y3XzJGwyS0GPwrDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?= MUWyN|U{ODd4OR?=
MFE296 MomzSpVv[3Srb36gRZN{[Xl? MoXqOVAxKG6P NWK0eYNLPSCm NWnWXJVHTE2VTx?= M3nXXYlv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF MWSyN|U{ODd4OR?=
HASMCs MV3GeY5kfGmxbjDBd5NigQ>? NHPmR|YxNTVyMDDuUS=> MWG2JIQ> MVXkc5dvNXKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCKQVTDJIFv\CClZXzsJJZq[WKrbHn0fS=> M2ixWlI{PTF6NE[3
U373 M3;PV2Z2dmO2aX;uJGF{e2G7 MVOwMlI2NzBwNT:xJO69VQ>? NF;2dWQzPCCq NIDpWZdqdmO{ZXHz[ZMhWFJvQjDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFVCgmGmQx?= NXPjN3hiOjN2N{SxO|E>
ARN8  NVL1fm5RTnWwY4Tpc44hSXO|YYm= MYSwMlA2NTJizszN M1vSTlI1KGh? NH33OXZz\WS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gdFU{NWSncHXu[IVvfCCpZX7ld{BjgSCQdYTsbY4uOw>? MYqyN|Q4ODV2MB?=
MCF7 MV;GeY5kfGmxbjDBd5NigQ>? MVOwMlA2NTJizszN NV\nSHZLOjRiaB?= NX\EfZM{emWmdXPld{B1cGViaX7keYN1cW:wIH;mJJA2Oy2mZYDlcoRmdnRiZ3Xu[ZMh[nliToX0cIlvNTN? NUPSdHd{OjN2N{C1OFA>
H1299  M1XWRmZ2dmO2aX;uJGF{e2G7 Ml31NE4{O+LCk{JCpOK2VQ>? M1\rO|I1NzR6IHi= NITqNZVFVVOR MmLxbY5kemWjc3XzJGUu[2GmaHXybY4heHKxdHXpckBt\X[nbIOg[I9{\SCmZYDlcoRmdnSueR?= NXfzbXFLOjN2NkG5O|U>
H1299 MU\GeY5kfGmxbjDBd5NigQ>? MUSwMlUh|ryP NYH3[2xUPDhiaB?= MoT2SG1UVw>? NWn1OlJTcW6qaXLpeJMhfGinIH3p[5JifG:{eTDwc5RmdnSrYXygZ49u[mmwZTD3bZRpKHOrbHnibY5qdg>? NGnwXHEzOzR4MUm3OS=>
H1299 NYm2[3RjTnWwY4Tpc44hSXO|YYm= NWT3SppXOC53IN88US=> MVq0PEBp NFTtV45FVVOR NFnhNYxqdmirYnn0d{B1cGViaX72ZZNqfmWwZYPzxsAh[2:vYnnu[UB4cXSqIIPpcIljcW6rbh?= Mmf2NlM1PjF7N{W=
MG-63  MlTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\oc4pQOC5|IN88US=> MVexNk06PiCq MYPEUXNQ NEfPOmVqdmirYnn0d{B1cGViY3XscEBoem:5dHigZ48ufHKnYYTt[Y51KHerdHigcYV1\m:{bXnu MX:yN|Q2OThzNx?=
LM8 NFz1bYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DHXVAvOyEQvF2= M{Xjb|EzNTl4IHi= MmWxSG1UVw>? NX7UOY53cW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJINwNXS{ZXH0cYVvfCC5aYToJI1mfG[xcn3pci=> Mlz1NlM1PTF6MUe=
K562 M4LMVWZ2dmO2aX;uJGF{e2G7 M4SzR|AvPSEQvF2= MViyOEBp Ml\N[ZRp[W6xbB?= Mmnz[IVkemWjc3XzJJRp\SCnbor5cYUh[WO2aY\peJkhd2ZiSFTBR5Mh[29vdILlZZRu\W62IIfpeIgh[3W{Y4XtbY4> M3u1O|I{PDNyOUW3
HEL MXvGeY5kfGmxbjDBd5NigQ>? NUjNZXpMOC53IN88US=> NWjJeHpKOjRiaB?= MUnleIhidm:u NX\seW86\GWlcnXhd4V{KHSqZTDlcpp6dWViYXP0bZZqfHlib3[gTGRCS3NiY3:teJJm[XSvZX70JJdqfGhiY4XyZ5VucW5? MVSyN|Q{ODl3Nx?=
HL60 Mn\HRZBweHSxc3nzJGF{e2G7 NXnlbWxMOSEQvF2= MojkNlQhcA>? MnvibY5lfWOnc9MgZ4VtdCCmZXH0bC=> MUeyN|QxODVzOR?=
KG1 MkfnRZBweHSxc3nzJGF{e2G7 NYLtcWRsOSEQvF2= NFvJXFQzPCCq M2DhRYlv\HWlZYRCpINmdGxiZHXheIg> Mn;5NlM1ODB3MUm=
Kazumi M1HBcWFxd3C2b4Ppd{BCe3OjeR?= NFjHdG4yKM7:TR?= NXPoWm1DOjRiaB?= M2jaNIlv\HWlZYRCpINmdGxiZHXheIg> NUTEbI1bOjN2MEC1NVk>
K562 M1\odmFxd3C2b4Ppd{BCe3OjeR?= MVqxJO69VQ>? M{Hvb|I1KGh? MXvpcoR2[2W|wrDj[YxtKGSnYYTo MmrpNlM1ODB3MUm=
THP1 NGfmS2xCeG:ydH;zbZMhSXO|YYm= MVqxJO69VQ>? M4q5[VI1KGh? M{T5dIlv\HWlZYRCpINmdGxiZHXheIg> NUiyU2c{OjN2MEC1NVk>
SH-SY5Y MWrGeY5kfGmxbjDBd5NigQ>? Ml[1NlUxKG6P MV:xOkBp MVHjbIFv\2W|IHX4dJJme3Orb36gdIF1fGW{bjDv[kBo\W6nczDpcpZwdH[nZDDpckBkcG:uZYP0[ZJwdCC|eX70bIV{cXNuIIXweIFs\SCjbnSg[YZndHW6 NXHqNIZSOjN|Mk[0NlI>
HEK293 NET2N5VHfW6ldHnvckBCe3OjeR?= MnnuNUDDvU4EoB?= MUexPEBpyqB? MWXpcohq[mm2czD0bIUhc2GuaYLpck04NW2nZHnheIVlKHKnY4L1bZRu\W62IH;mJJN6dnCqaXzpck0yKGGpZ4Ll[4F1\XNiaX70c{Bi\2e{ZYPvcYV{ M1zzNlI{Ojh2OES4
HTK MnS0SpVv[3Srb36gRZN{[Xl? NVXGflJvPDByIH7N NYHFT4JwPzJiaB?= MljabY5pcWKrdIOgWGdHNc7{4pETTY5lfWOnZDDNfY9ncWK{b3LsZZN1KESrZn\ldoVvfGmjdHnvci=> NVG4RWxVOjN{OESwNFI>
HTK M1rGS2Z2dmO2aX;uJGF{e2G7 M3\rXlExOC16MEDuUS=> NVS3Z4dXPzJiaB?= NGrTU2xjdG:la4OgWGdHNc7{4pETTY5lfWOnZDDSU3Mh[W6mIFiyU|LDqEGlY4XteYxifGmxbh?= NXXodHJmOjN{OESwNFI>
Caco-2  M3:0fmZ2dmO2aX;uJGF{e2G7 MnzBNUDDvU4EoB?= MkLpNlQhcA>? NELUOZNl\WO{ZXHz[ZMhW0WUVDDwdo91\WmwIHX4dJJme3Orb36= NIrId2gzOzF7NUC3NC=>
HeLa NVLCNY81T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIG3[IsyODBibl2= MYCyOEBp M2\GVGROW09? MmHkTWM2OCCxZjCxNFBvVQ>? NH3qWpczOzF4NUe0PC=>
HeLa M4TH[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXP6cHhbPDBibl2= NFLaW2w1QCCq M1jVTWROW09? MkTzTWM2OCCxZjC0NI5O NXfTemlmOjNzNkW3OFg>
HeLa NH:4PW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TpTlIxKG6P NWLFOnNzPzJiaB?= M3nrWWROW09? M2fGeGlEPTBib3[gNlBvVQ>? NWTWW|NUOjNzNkW3OFg>
HeLa NFv6NGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPHWJd[OTBxM{CvOVAhdk1? NUHCXJM2PzJiaB?= MmLvSG1UVw>? MojXbY5kemWjc3XzJJRp\SCwdX3i[ZIhd2ZiTV3QJEjPnM7qbTmgcI9{eyClZXzsd{Bld3OnIHTldIVv\GWwdHz5 NFXOSnEzOzF4NUe0PC=>
MDA-MB-231 MlTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWCyOU01ODBibl2= MnrpOFghcA>? NHfB[WNKSzVyIH;mJFI3Oy5{bl5CpC=> NVHDW29IOjNyNUWxPVg>
MCF-7  MlzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnXbI0zPS12MECgcm0> M4C2U|Q5KGh? M{D6R2lEPTBib3[gNlIxNjSwTR?= MUCyN|A2PTF7OB?=
ECC-1  M1X0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYixNFAhdk1? NIP4UlAzPCCq NFfVVGhmfGijbn;s MUXpcoNz\WG|ZYOgeIhmKHC{b4DvdpRqd25ib3[gZZBweHSxdHnjJI52[2ynaTD0c{A{PSV? MnPDNlMxOjh6MEO=
HEC-1A MkDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nZS|ExOCCwTR?= M1;1RVI1KGh? MW\leIhidm:u MkT2bY5kemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJIFxd3C2b4TpZ{BvfWOuZXmgeI8hOzln NV76fJpnOjNyMki4NFM>
NHAC-kn NWG3cHJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\Z[|ExNzFyMD:1NFAhdk1? MmPhNVIhcA>? M4\yZmROW09? NG\TfnhKSzVyIH;mJFUxOG6P MlT0NlMxOTd6N{G=
A549 NH2z[HBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHeyWngzPTBibl2= M1znelYuPzJiaB?= MnvzSG1UVw>? MWXjZZV{\XNiYTDndoVifGW{IHnubIljcXSxcomg[YZn\WO2IHPvcYJqdmVid3n0bEBVYFRib4Kg[ZJtd3Srbnni NX7rSIZIOjJ7OUS3PFA>
MG-63 NYfHR2tET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUKzNFAhdk1? MXSxNkBp MkLhSG1UVw>? MV;pcohq[mm2czD0bIUh[2WubDDndo94fGhidH:gPFYm NHrtTZkzOjd7OUOzPC=>
MG-63 MkPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DRRlMxOCCwTR?= NEXGW20zPCCq NIrrUWZFVVOR NIDsVXpqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hPjdn M1KxZVIzPzl7M{O4
MG-63 NGnhOYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NICzZ4I{ODBibl2= NILRdGo1QCCq M1vnTGROW09? NUHZO4ZXcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDV4JR?= NIjiN3QzOjd7OUOzPC=>
HL60  NIXN[m5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHXNVUxNTN3MDDuUS=> M33CdVI1KGh? NUT3NndzcW6lcnXhd4V{KGOnbHygZZBweHSxc3nzxsB4cGWwIHPvcoNmdnS{YYTpc45{KGirZ3jldkB1cGGwIEK1NEBvVQ>? MVqyNlc2Ozd|OR?=
U937 NHzCfVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILVUosyPTBvM{WwJI5O NXfXdHo3OjRiaB?= NFz1WmRqdmO{ZXHz[ZMh[2WubDDhdI9xfG:|aYRCpJdp\W5iY3;uZ4VvfHKjdHnvcpMhcGmpaHXyJJRp[W5iMkWwJI5O NFXj[VczOjd3M{ezPS=>
SCC-6 MnLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXX5TJpjOjByLUOyNFAhdk1? MmLmNVIwOjRxNEigbC=> MkP4SG1UVw>? M37jNYlvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJI9nKFOFQz22JINmdGy|IHnuJIEh\G:|ZT2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= M37NeFIzPTV{M{Kx
U87  M2DibGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zVNFExOC1|MECgcoc> MUeyOEBp NGHadJRqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hPzJnIDDheEAzODCwZx?= M2PielIzOjdyOES5
K562 NFG0e2JHfW6ldHnvckBCe3OjeR?= MoDkNUDPxE1? MUCxNkBp M{XlVGROW09? MX\lcohidmOnczD0bIUh\XiycnXzd4lwdiCxZjDSWW5ZOyCrbnT1Z4VlKGK7IEWtZZpiNUOmUh?= Mk\NNlIyPzlzOUi=
Reh M4HSPGZ2dmO2aX;uJGF{e2G7 MWSwMlMwOSEQvF2= MUCxNkBp Mn;USG1UVw>? NXTjeXVM\W6qYX7j[ZMhfGinIHX4dJJme3Orb36gc4YhWlWQWEOgbY5lfWOnZDDifUA2NWG8YT3D[HI> MXiyNlE4QTF7OB?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
EGFR / STAT3 ; 

PubMed: 31289542     


Expression of EGFR and STAT3 in PC3 cells treated with TSA. PC3 cells were plated in 6-cm dishes, and 0.25, 0.5 or 1 µM TSA was added for 24 h. DMSO was added into the control group wells. Cells were collected and lysed with lysis buffer and the protein expression analyzed via western blotting.

Cyclin D1 / CDK6 / CDK4 / p-RB / RB; 

PubMed: 31289542     


Expression of cyclin D1, CDK6, CDK4 and RB, and the phosphorylation of RB, was detected in PC3 cells treated with TSA for 24 h. 

MMP-1 / MMP-3 / MMP-13 / TIMP-1; 

PubMed: 27431944     


Chondrocytes were pretreated with increasing concentrations of TSA for 2 h, followed by stimulation with 5 ng/ml IL-1β for 24 h.

Acetyl-H3 (Lys27) / H3 (96C10) / Acetyl-H4(Lys8) / H4(L64C1); 

PubMed: 27431944     


Chondrocytes were treated with increasing concentrations of TSA for 24 h.

α-H3Ac / α-H4Ac / α-H3K9Ac / α-H3K9 S10 / α-H3K4 me / α-H3K4 me2 / α-H3K9 me2; 

PubMed: 23802098     


Histone acetylation occurs directly at the promoter region of IL-23R. The ChIP assay demonstrates that TSA treatment results in an increase in the acetylation of histone H3 and H4. A549 cells were cultured in the presence or absence of TSA (250 ng/mL) for a period of 24 h. Subsequently, a ChIP assay was performed using the following antibodies; pan acetyl-histone H3 (H3Ac), pan acetyl-histone H4 (H4Ac), acetyl-histone H3 Lys 9 (H3K9Ac), acetyl-histone H3 Lys 9/14 (H3K9/14ac), acetyl-histone H3 Lys 9 phosphoSer10 (H3K9S10), methyl-histone H3 Lys 4 (H3K4Me), di methyl-histone H3 Lys 4 (H3K4Me2), and di methyl-histone H3 Lys 9 (H3K9Me2). Input DNA serves as a positive control as recommended by the manufacturer (Diagenode). A no antibody control was included to test for non-specific binding (UT, untreated; TSA, Trichostatin A).

31289542 27431944 23802098
Immunofluorescence
α-C/EBPβ / α-HP1α ; 

PubMed: 21122806     


3T3-L1 preadipocytes were grown on coverslips for three days and induced to differentiate by treatment with MDI (48 h) in the presence of vehicle (-TSA) or 87 nM Trichostatin A (+TSA). Under these experimental conditions: A-H Cells were fixed and permeabilized in cold methanol, subjected to IIF with the indicated antibodies, and nuclei were counterstained with DAPI. Scale bar, 5 μm. 

α-HDAC1 ; 

PubMed: 29045501     


MCF-7 cells were treated with indicated concentrations of trichostatin A (optical sections E-H, respectively) for 12 hours, fixed, permeabilized and optical sections were obtained by laser scanning confocal microscopy. Fluorescence signal for HDAC1 is shown in green (left panels), DAPI staining is shown in blue (middle panels), and merged optical sections are shown in the right panels.

α-tubulin / acetylated histone 3; 

PubMed: 27957719     


Immunocytochemistry for acetylated α-tubulin (red) and acetylated histone 3 (green) on N2a cells treated with 1 μM TSA, ACY-738, and ACY-775.

21122806 29045501 27957719
Growth inhibition assay
Cell viability (A549 cells); 

PubMed: 27571418     


Cytotoxicity of histamine determined by MTT assay in A549 cells.

Cell viability (MDA-MB-231 cells); 

PubMed: 27548148     


The human breast cancer cells (MDA-MB-231) were incubated with various concentrations of TSA (0–300 nM) for 24 h. Cell viability was measured by WST-8.

Cell viability (PC3 cells); 

PubMed: 31289542     


PC3 cells were plated in a 96-well plate and treated with different doses of TSA (0, 0.25, 0.5 and 1 µM) for 72 h; an MTT assay was used to measure the effects of TSA on PC3 cell proliferation.

27571418 27548148 31289542
In vivo Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. [1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. [5]

Protocol

Kinase Assay:

[1]

- Collapse

In vitro HDAC activity:

Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×105 cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 106 cpm) of [3H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [3H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [3H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.
Cell Research:

[1]

- Collapse
  • Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3
  • Concentrations: Dissolved in absolute ethanol, final concentrations ~10 μM
  • Incubation Time: 96 hours
  • Method:

    Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU
  • Formulation: Dissolved in DMSO
  • Dosages: ~5 mg/kg/day
  • Administration: Injection s.c.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 23 mg/mL (76.05 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 302.4
Formula

C17H22N2O3

CAS No. 58880-19-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03901053 Not yet recruiting Device: Reaktiv AFO|Device: PhatBrace AFO Foot Injuries and Disorders Jason Wilken|Minneapolis Veterans Affairs Medical Center|Walter Reed National Military Medical Center|Henry M. Jackson Foundation for the Advancement of Military Medicine|Center for Veterans Research and Education|University of Delaware|Johns Hopkins Bloomberg School of Public Health|University of Iowa June 2019 Not Applicable
NCT03887650 Recruiting Drug: Liposomal Bupivicaine 1.3%|Drug: Bupivacaine 0.5% Post-operative Pain|Total Shoulder Arthroplasty|Osteoarthritis of the Shoulder|Pain Management Hartford Hospital January 14 2019 Phase 4
NCT03838926 Recruiting Drug: Trichostatin A Relapsed or Refractory Hematologic Malignancies Vanda Pharmaceuticals September 27 2018 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?

  • Answer:

    Our S1045 Trichostatin A (TSA) is R enantiomer.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Trichostatin A (TSA) | Trichostatin A (TSA) supplier | purchase Trichostatin A (TSA) | Trichostatin A (TSA) cost | Trichostatin A (TSA) manufacturer | order Trichostatin A (TSA) | Trichostatin A (TSA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID